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Nicotine is the major addictive substance in cigarettes, and genes involved in sensing nicotine are logical candidates
for vulnerability to nicotine addiction. We studied six single-nucleotide polymorphisms (SNPs) in the CHRNA4
gene and four SNPs in the CHRNB2 gene with respect to nicotine dependence in a collection of 901 subjects (815
siblings and 86 parents) from 222 nuclear families with multiple nicotine-addicted siblings. The subjects were
assessed for addiction by both the Fagerstrom Test for Nicotine Dependence (FTND) and the Revised Tolerance
Questionnaire (RTQ). Because only 5.8% of female offspring were smokers, only male subjects were included in
the ﬁnal analyses (621 men from 206 families). Univariate (single-marker) family-based association tests (FBATs)
demonstrated that variant alleles at two SNPs, rs1044396 and rs1044397, in exon 5 of the CHRNA4 gene were
signiﬁcantly associated with a protective effect against nicotine addiction as either a dichotomized trait or a quan-
titative phenotype (i.e., age-adjusted FTND and RTQ scores), which was consistent with the results of the global
haplotype FBAT. Furthermore, the haplotype-speciﬁc FBAT showed a common (22.5%) CHRNA4 haplotype,
GCTATA, which was signiﬁcantly associated with both a protective effect against nicotine addiction as a dichot-
omized trait ( , ) and signiﬁcant decreases of age-adjusted FTND ( , ) orZp53.04 P ! .005 Zp53.31 P ! .005
RTQ scores ( , ). Our ﬁndings provide strong evidence suggesting a common CHRNA4 hap-Zp52.73 Pp .006
lotype might be protective against vulnerability to nicotine addiction in men.
Nearly one-third of adults worldwide are smokers, and
the majority started the habit as adolescents (World
Health Organization 1997). In 2000, smoking caused
∼2.43 million deaths in industrialized countries (∼19%
of total adult mortality) and ∼2.41 million deaths in de-
veloping countries (∼9% of total adult mortality) (Ezzati
and Lopez 2003).
Smoking cigarettes is both psychologically and physi-
ologically addictive (Nair and Brandt 2000). A vast body
of literature indicates that nicotine is the component of
tobacco smoke that leads to addiction (Stolerman and
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Jarvis 1995). Nicotine addiction (i.e., tobacco addiction
[MIM #188890]), like many other drug dependencies, is
believed to be a complex, multifactorial behavior with
both genetic and environmental determinants. Twin and
adoption studies have shown that heritabilities of vul-
nerabilities for both smoking initiation (SI) and smoking
persistence (SP) are at least 50% (Li 2003). A familial
aggregation study among siblings of nuclear families (Niu
et al. 2000) also suggests that genetic inﬂuences may be
an important determinant in vulnerability to nicotine ad-
diction. Furthermore, studies using animal models found
that genetic factors play a critical role in both behavioral
and physiological effects of nicotine (Batra et al. 2003).
However, the identiﬁcation of nicotine-addiction genes
has lagged far behind environmental risk-factor classiﬁ-
cation (Straub et al. 1999; Batra et al. 2003).
Nicotine functions by binding to nicotinic acetylcho-
line receptors (nAChRs), which, in turn, modulate the
release of dopamine in the mesolimbic system (Pido-
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plichko et al. 1997). To date, nine a (a2–a10) and three
b (b2–b4) subunit genes have been identiﬁed (Mans-
velder and McGehee 2002). Among them, a4 and b2
subunits are the most widely and concurrently expressed
high-afﬁnity nAChR subunits in the brain (Mathieu-Kia
et al. 2002) and are both upregulated under chronic
nicotine exposure (Whiteaker et al. 1998). The gene that
encodes the human nAChR a4 subunit (CHRNA4
[MIM 118504] [National Center for Biotechnology In-
formation {NCBI} locus ID 1137]) was mapped by
FISH to 20q13.2-13.3 (Steinlein et al. 1994). The gene
is ∼17 kb in size and comprises six exons (Steinlein et
al. 1996). The nAChR b2 subunit gene (CHRNB2 [MIM
118507] [NCBI locus ID 1141]) was ﬁrst mapped by
FISH to chromosome 1q21 (Rempel et al. 1998) and
was further narrowed to chromosome 1q21.3 (Lueders
et al. 1999). The genomic sequence of the CHRNB2
gene is ∼12 kb and comprises six exons (Lueders et al.
2002). Genetic polymorphisms in the CHRNA4 gene
have been reported to be associated with autosomal
dominant nocturnal frontal lobe epilepsy (Hirose et al.
1999; Chioza et al. 2000; Steinlein et al. 2000; Rozy-
cka et al. 2003), attention-deﬁcit/hyperactivity disorder
(ADHD) (Kent et al. 2001; Todd et al. 2003), Alzheimer
disease (Kawamata and Shimohama 2002), and febrile
convulsions (Chou et al. 2003), but there has been no
prior study of the association of this gene with addictive
behaviors. Studies on CHRNB2 gene variants are also
quite limited, with two previous studies showing no as-
sociations with nicotine dependence (Silverman et al.
2000; Lueders et al. 2002).
To identify families affected by nicotine addiction, we
screened a population of ∼25,000 siblings, aged 20–60
years, from November 2000 to July 2001, by use of the
Fagerstrom Test for Nicotine Dependence (FTND)
(Heatherton et al. 1991; Niu et al. 2000). The siblings
resided in a relatively remote region (Huoqiu County)
of Anhui Province, China. A total of 901 subjects (815
siblings [age 47.0 years  10.1 years, men 78.8%]; 86
parents) from 222 qualiﬁed nuclear families (22 [9.9%]
families had both parents, 42 [18.9%] families had one
single parent, and 158 [71.2%] families had no available
parents) were ﬁnally recruited. The criteria used for sub-
ject selection were as follows: (1) at least two siblings,
aged 20–60 years, with FTND scores8 and (2) at least
one parent or one additional sibling. In addition to the
FTND, the Revised Tolerance Questionnaire (RTQ)
(Tate and Schmitz 1993) was also administered to eli-
gible individuals. All subjects gave their written informed
consent, and the study protocol was approved by the
institutional review boards of the Harvard School of
Public Health and the AnhuiMedical University. Because
only 10 women offspring were smokers (5.8%), all
women and nonsmoking male offspring were excluded
in the ﬁnal analyses. A total of 621 male subjects from
206 nuclear families were ﬁnally used in the analysis.
Among the 577 smoking male offspring, FTND scores
(8.1  2.1) and RTQ scores (35.1  7.0) were found
to be moderately but signiﬁcantly correlated (Pearson
correlation coefﬁcient , ), which wasrp 0.52 P ! .0001
in accord with results of other independent studies (Tate
and Schmitz 1993; Niu et al. 2000).
A SNP set of 30 CHRNA4 SNPs and 24 CHRNB2
SNPs from NCBI dbSNP (dbSNP Home Page) or pub-
lished literatures was evaluated by the PCR-RFLPmethod
in a panel of 45 previously established B-lymphoblastoid
cell line DNA samples from the same geographical region.
Among the 54 SNPs evaluated, 18 (33.3%)were validated
to be polymorphic (CHRNA4, 14 SNPs; CHRNB2, 4
SNPs). From the 14 CHRNA4 SNPs, we excluded 1 low-
heterozygosity (HET) SNP (i.e., HET18%;minor allele
frequency [MAF]10%), as well as an additional 7 SNPs
that were in perfect linkage disequilibrium (LD) with at
least one of the remaining six CHRNA4 SNPs (the extent
of LD was measured by use of FD′F, which was calculated
according to Lewontin [1964]). Finally, we handpicked
sixCHRNA4 SNPs and fourCHRNB2 SNPs on the basis
of both HET ( , which implies )HET 1 18% MAF 1 10%
and pairwise LD ( FD′F ) criteria. Large-scale0.5 !  1.0
genotyping for these 10 SNPs in the 901 DNA samples
was performed by use of either PCR-RFLP or PCR-OLA
(oligonucleotide ligation assay). The PCR primer se-
quences (designed by use of the Primer3 or SNPkit [Hao
et al. 2002]), as well as genotyping methods, are sum-
marized in table A1 (online only).
The distributions of the six CHRNA4 SNPs and
the four CHRNB2 SNPs are depicted in ﬁg. 1A and
1b, respectively. Among the six SNPs residing in the
CHRNA4 gene, rs1044396 (CrT transition; SerrSer)
and rs1044397 (GrA transition; AlarAla) are synony-
mous changes located in exon 5, whereas all others are
located either in an intronic region (rs2273504 [GrA
transition], rs2273502 [CrT transition], rs3827020
[TrC transition]) or in the 3′ UTR region (rs2236196
[ArG transition]). Among the four SNPs residing in the
CHRNB2 gene, rs2072658 (GrA transition) is located
in the 5′ UTR region, whereas A10160C is located at
intron 5, and rs2072660 (CrT transition) and rs2072661
(GrA transition) are located in the 3′ UTR. In the DNA
panel of 45 cell line samples, all 10 SNPs had a MAF 1
and all were in Hardy-Weinberg equilibrium (10% P 1
in respective x2 tests)..05
The pairwise FD′F values for the six CHRNA4 SNPs
were found to be quite high (range 0.84–1.00, median
1.00) (ﬁg. 2A), which indicates that these six SNPs can
be considered to be one haplotype block. Similarly, the
fourCHRNB2 SNPs were also found in almost complete
LD with respect to each other (range 0.86–1.00, median
1.00) and, therefore, could also be grouped in one block
(ﬁg. 2B). Thus, we either analyzed one SNP at a time
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Figure 1 A, Schematic representation of the six SNPs located on the CHRNA4 gene, showing their locations according to the information
from the chromosome 20 genomic contig (GenBank accession number NT_011333). SNP1 and SNP2 in exon 5 are synonymous SNPs revealed
by direct DNA sequencing. B, Schematic representation of the four SNPs located on the CHRNB2 gene, showing their locations according to
the information from the chromosome 1 genomic contig (GenBank accession number NT_004668).
by use of univariate (single-marker) family-based asso-
ciation tests (FBATs) or considered SNPs that were on
the same gene as a single haplotype block and tested the
associations by use of the haplotype FBAT for various
nicotine-addiction phenotypes (both qualitative and
quantitative). As mentioned above, all analyses were per-
formed in men only. In the univariate FBAT, a signiﬁcant
association of CHRNA4 rs1044396 (the variant T allele
is the protective allele) ( , polymorphismMAFp 0.286
information content [PIC] , calculated by use ofp 0.325
the POLYMORPHISM software [Niu et al. 2001]) was
consistently shown across all addiction-related pheno-
types: nicotine addiction (addicted and nonaddicted pa-
tients with FTND scores of 8 and 2, respectively)
( ), age-adjusted FTND score ( ), and age-P ! .01 P ! .01
adjusted RTQ score ( ) before Bonferroni cor-P ! .01
rection. Similarly, rs1044397 ( ,MAFp 0.416 PICp
), which is in almost complete LD with rs10443960.368
(FD′F p 1.00) (the variant A allele is the protective
allele), was observed to be signiﬁcantly associated with
nicotine addiction ( ) before Bonferroni correctionP ! .01
and with age-adjusted FTND and RTQ scores (P !
for both) after Bonferroni correction for multiple.001
comparisons (for 10 SNPs being tested individually, the
global signiﬁcance level needs to be adjusted to
) (table 1). For CHRNB2, no SNP was0.05/10p 0.005
found to be signiﬁcantly associated with any nicotine-
addiction phenotype (table 1).
Because haplotype-based analysis is arguably more
powerful than single-marker analysis (Niu et al. 2002),
we performed the global haplotype FBAT as the main
haplotype test. In all FBAT analyses, we used both the
age-adjusted FTND score and the age-adjustedRTQscore
as the continuous phenotypes. For CHRNA4, the global
test of the haplotype FBAT demonstrated a signiﬁcant
association of the haplotypes formed by rs2273504,
rs2273502, rs1044396, rs1044397, rs3827020, and
rs2236196 (in the direction 5′r3′) with both nicotine ad-
diction ( , 4 df, ) and the age-adjusted2x p 19.19 P ! .001
FTND score ( , 5 df, ), even after Bon-2x p 17.96 P ! .005
ferroni correction (for two genes, the signiﬁcance level is
adjusted to be 0.05/2p 0.025). In addition, a signiﬁcant
association was observed with regard to the age-adjusted
RTQ score ( , 4 df, ) before Bonferroni2x p 10.43 P ! .05
correction (table 2). For CHRNB2, the global test shows
that the haplotypes formed by rs2072658, A10160C,
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Table 1
Univariate FBAT for Association of CHRNA4 and CHRNB2 SNPs with Nicotine-Addiction
Phenotypes
GENE
AND SNP VARIANT MAF
RESULT FOR PHENOTYPE
Nicotine
Addictiona FTND Score RTQ Score
Z P Z P Z P
CHRNA4:
rs2273504 A .441 .753 .452 1.284 .199 .845 .398
rs2273502 T .179 2.13 .033b 2.497 .013b 1.704 .088
rs1044396 T .286 2.673 .008b 2.832 .005b 2.724 .006b
rs1044397 A .416 2.699 .007b 3.781 !.001c 3.505 !.001c
rs3827020 C .399 .237 .813 .602 .547 .265 .791
rs2236196 G .185 1.834 .067 1.828 .067 1.169 .242
CHRNB2:
rs2072658 A .19 .628 .530 1.692 .091 .821 .412
A10160C C .2 1.143 .253 1.686 .092 .912 .362
rs2072660 T .278 1.646 .100 1.515 .130 1.052 .293
rs2072661 A .283 1.36 .174 1.152 .249 .972 .331
NOTE.—The univariate FBAT was performed by use of the additive model. The minor allele
is also referred to as the “variant allele” in the text. MAFp minor (i.e., variant) allele frequency.
SNPs are listed in order (5′r3′) for each gene. Both rs1044396 and rs1044397 are shown in bold
italics because they were consistently signiﬁcant before Bonferroni correction for nicotine addic-
tion, as well as FTND and RTQ scores. Both FTND and RTQ scores were age-adjusted.
a When nicotine addiction was considered as a dichotomized trait, the addicted andnonaddicted
subjects were deﬁned as having scores of 8 and 2, respectively (Fagerstrom et al. 1990).
b Signiﬁcant only before Bonferroni correction (i.e., ).P ! .05
c Signiﬁcant after Bonferroni correction (i.e., ).P ! .005
rs2072660, and rs2072661 (in the direction 5′r3′) yielded
marginally signiﬁcant association with the age-adjusted
FTND score ( , 4 df, ) before Bonfer-2x p 8.84 Pp .065
roni correction but demonstrated no association with nic-
otine addiction as a dichotomized trait ( , 4 df,2x p 7.05
) or with the age-adjusted RTQ score ( 2P 1 .10 x p
, 4 df, ) (table 2). The association with age-3.23 P 1 .10
adjusted FTND score was no longer statistically signi-
ﬁcant after Bonferroni correction. By use of the expec-
tation-maximization algorithm implemented in the
haplotype FBAT, four major haplotypes (i.e., frequency
0.05) were revealed for bothCHRNA4 andCHRNB2.
Haplotype-speciﬁc tests (haplotype FBATs) were used to
analyze the effects on nicotine addiction, age-adjusted
FTND score, and age-adjusted RTQ score for each hap-
lotype, compared with all other haplotypes grouped to-
gether on each gene. The GCTATA haplotype of the
CHRNA4 gene, bearing the variant alleles at both
rs1044396 and rs1044397 (underscored), was found to
be signiﬁcantly associated with a protective effect
against nicotine addiction ( , ), asZp 3.04 Pp .002
well as signiﬁcant decreases of age-adjusted FTND score
( , ) and age-adjusted RTQ scoreZp 3.31 Pp .001
( , ) after Bonferroni correction.Zp 2.73 Pp .006
These results were highly consistent with the univariate
FBAT results showing that the variant alleles at both of
these two exonic SNPs had signiﬁcant protective effects.
For CHRNB2, we found that the haplotype GCCG was
associated with a signiﬁcant protective effect against nic-
otine addiction ( , ), as well as aZp 2.13 Pp .033
signiﬁcant decrease of age-adjusted FTND score (Zp
, ) before Bonferroni correction, but2.13 Pp .033
such associations were no longer statistically signiﬁcant
after Bonferroni correction (table 3).
Because both rs1044396 and rs1044397 were located
on exon 5 of the CHRNA4 gene, we sequenced exon 5
and its ﬂanking regions (50 bp upstream and 50 bp down-
stream) in a selected sample of 36 subjects (7 parents and
29 offspring) from 25 nuclear families with extreme Z
values. Among the 29 offspring, 22 subjects had FTND
scores 8 and 7 subjects had FTND scores2. Sequenc-
ing results conﬁrmed the three genotyped SNPs in this
region—rs1044396, rs1044397, rs3827020—and re-
vealed two new synonymous polymorphisms in exon 5,
which have been indicated in ﬁgure 1. The MAFs of
SNP1 (AsprAsp) and SNP2 (ProrPro) were 0.237 and
0.257, respectively, in the sequenced subjects. Both SNP1
and SNP2 have been recently reported in dbSNP
(dbSNP Home Page), corresponding to rs1044393 and
rs2229959, respectively.
Our study is the ﬁrst to demonstrate signiﬁcant asso-
ciations, not only of individual CHRNA4 SNPs but also
of a multilocus CHRNA4 haplotype, with vulnerability
to nicotine addiction in men. To our knowledge, there
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Table 2
Global (Multihaplotype) Tests of the Haplotype
FBAT for Association of CHRNA4 and CHRNB2
SNPs with Nicotine-Addiction Phenotypes
Gene and
Phenotype x2 df P Value
CHRNA4:
Nicotine addiction 19.19 4 .0007a
FTND score 17.96 5 .003a
RTQ score 10.43 4 .034b
CHRNB2:
Nicotine addiction 7.05 4 .133
FTND score 8.84 4 .065
RTQ score 3.23 4 .520
NOTE.—The haplotype FBAT was performed
by use of the additive model. Globally signiﬁcant
results are shown in bold italics.
a Signiﬁcant after Bonferroni correction (i.e.,
).P ! .025
b Signiﬁcant only before Bonferroni correction
(i.e., ).P ! .05
Figure 2 A, Pairwise LD for the 15 CHRNA4 SNP pairs, evaluated by FD′F. B, Pairwise LD for the six CHRNB2 SNP pairs, evaluated
by FD′F. Because all SNP pairs have high FD′F values, we presented x2 values inside their corresponding boxes.
have been no prior studies regarding the role of molecular
variants of the human CHRNA4 gene in addictive be-
havior, although two groups have linked this gene to at-
tention problems such as ADHD (Kent et al. 2001; Todd
et al. 2003). A biological link between CHRNA4 or
CHRNB2 and the nicotine-addiction phenotype has been
well established by multiple studies in animal models. By
constructing a4 nAChR subunit knockout mice, Ross et
al. (2000) conﬁrmed that the a4 nAChR subunit plays a
pivotal role in anxiety in mice. Actually, several in vitro
studies showed that a number of nAChR agonists that
bind to a4b2 receptor complexes have anxiolytic-like
effects (Pomerleau 1986; Gilbert et al. 1989; Brioni et
al. 1993), and nicotine is shown to reduce anxiety in
chronic smokers (Pomerleau 1986; Gilbert et al. 1989),
allowing them to relax, focus, and work more efﬁciently.
Furthermore, knock-in mice with a LeurSer mutation (a
point mutation in the M2 transmembrane domain) in the
a4 nAChR subunit demonstrated increased anxiety and
showed a reduced nigrostriatal dopaminergic function
(Labarca et al. 2001). With regard toCHRNB2, nicotine-
evoked dopamine release is abolished (Zhou et al. 2001)
and nicotine self-administration is attenuated (Picciotto
et al. 1998) in b2 nAChR subunit knockout mice.
A biological link between CHRNA4 orCHRNB2 and
nicotine-addiction phenotypes has also been suggested
by multiple studies in humans. Human a4b2 nAChRs
are functionally upregulated by chronic nicotine expo-
sure (Buisson and Bertrand 2001), and these receptors
are more likely to enter desensitization states (Fenster et
al. 1999) than without such exposure. Moreover, the
increased numbers of a4b2 nAChRs in the human post-
mortem brain signiﬁcantly correlated with intensity and
duration of smoking history (Breese et al. 1997). When
nicotine is avoided, the excess number of a4b2 nAChRs
will recover from desensitization, resulting in hyperex-
citability at cholinergic synapses that could contribute
to the unrest and agitation that, in turn, motivate the
smoker to smoke the next cigarette, to re-desensitize
these excess nAChRs (Dani and De Biasi 2001). Todd
et al. (2003) identiﬁed an intron 2 SNP in the CHRNA4
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Table 3
Haplotype-Speciﬁc Tests of the Haplotype FBAT for Association of CHRNA4 and
CHRNB2 SNPs with Nicotine-Addiction Phenotypes
GENE AND
HAPLOTYPE FREQUENCY
RESULT FOR PHENOTYPE
Nicotine
Addiction FTND Score RTQ Score
Z P Z P Z P
CHRNA4:
ACCGCA .381 1.865 .062 2.432 .015 1.875 .061
GCTATA .225 3.039 .002a 3.312 .001a 2.727 .006a
GTCGTG .153 2.297 .022b 2.424 .015b 1.713 .087
GCCATA .129 .765 .444 .310 .756 .063 .950
CHRNB2:
GACG .418 .179 .858 1.529 .126 .805 .421
GATA .225 1.979 .048b 1.828 .068 1.185 .236
GCCG .163 2.134 .033b 2.128 .033b .848 .396
AACG .135 .17 .865 1.406 .160 1.297 .195
NOTE.—The haplotype-speciﬁc test of the haplotype FBAT was performed by use of
the additive model. The nucleotides at rs1044396 and rs1044397 of CHRNA4 and the
nucleotides at rs2072658 and A10160C are underscored for comparisonswith the single-
marker FBAT results of the respective SNPs in table 1. Only haplotypes with frequencies
.05 are presented. Globally signiﬁcant results are shown in bold italics.
a Signiﬁcant after Bonferroni correction (i.e., ).P ! .00625
b Signiﬁcant only before Bonferroni correction (i.e., ).P ! .05
gene that was associated with a severe inattention prob-
lem. Since nicotine and nicotine agonists enhance atten-
tion among ADHD patients in clinical trials, some smok-
ers with inattention problems may be addicted to nico-
tine because such addictive smokers can enhance atten-
tion through persistent self-administration of nicotine.
The pathway to substance dependence is complex and
involves multiple genetic and environmental risk factors
(Kendler et al. 1999; Swan 1999). By use of both uni-
variate and haplotype FBATs, the present study found
signiﬁcant associations of two CHRNA4-coding SNPs,
rs1044396 and rs1044397, with protective effects against
nicotine addiction. Although these two SNPs do not result
in amino acid changes, rs1044397 was located in a highly
conserved protein motif, TKAP (see the boxed area of ﬁg.
A1 [online only]), across humans, chimpanzees, rhesus
monkeys, rats, and mice. The most frequent haplotype in
our study population contains the C allele at rs1044396
and the G allele at rs1044397 (i.e., ACCGCA population
frequency 38.1%), and, therefore, the protective haplo-
type revealed here, GCTATA, carried the variant alleles
at both SNP sites (table 1).
Our haplotype-analysis results provided some sug-
gestive evidence of a tentative association of CHRNB2
SNPs with vulnerability to nicotine addiction, but such
results were uniformly insigniﬁcant after Bonferroni cor-
rection and therefore should be considered as principally
negative. In agreement with our results, Lueders et al.
(2002) undertook both single-marker and haplotype ap-
proaches and did not ﬁnd any association of CHRNB2
variants with nicotine dependence as either a continuous
or a dichotomous variable. Silverman et al. (2000) an-
alyzed four SNPs on CHRNB2 in 872 subjects and also
found no signiﬁcant association with either SI or pro-
gression to nicotine dependence.
Our study focused exclusively on men. Perkins et al.
(1999) discussed the emerging evidence that men and
women differ in their responses to smoking, presumably
because of both genetic and environmental factors. The
relative importance of “non-nicotine” factors has been
shown to be greater for women than for men, including
factors such as pleasure from social reinforcements for
smoking and comforts gained from having something to
manipulate in social activities. Faraday et al. (1999) also
pointed out that women are more inclined to view smok-
ing as a useful tool to cope with social stress or un-
pleasant situations. Probably because of these reasons,
women have been less successful than men in using nic-
otine-replacement therapy for quitting smoking. Thus, ge-
netic factors underlying nicotine addiction probably play
a different role in female and male smokers. In a meta-
analysis in male and female twins, Li et al. (2003) found
that genetic factors play a more signiﬁcant role for SI but
a less signiﬁcant role for SP in female adults compared
with male adults. Signiﬁcant sex difference was also de-
tected in shared environmental factors for SI and SP.How-
ever, no signiﬁcant sex difference was detected for non-
shared environmental effects for either phenotype.
Despite limitations, including an exclusively male sam-
ple and a single ethnic group, our study has several unique
strengths. First, we applied both univariate and haplotype
FBATs (they both allow for the analyses of dichotomized
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or continuous traits), which are state-of-the-art tests of
association in the presence of linkage (Lake et al. 2000;
Horvath et al. 2004) on the basis of the Rabinowitz-Laird
algorithm (Rabinowitz and Laird 2000). The FBAT is a
generalized version of the classic transmission/disequilib-
rium test, which can be applied to any type of nuclear
family study (Laird et al. 2000), thus avoiding the thorny
problem introduced by population admixture that is com-
monly seen in case-control study designs involving mul-
tiple ethnic groups. Moreover, the FBAT results (both
single-marker and haplotype-based) without age ad-
justments were quite similar to the results with adjust-
ments for age (data not shown).
Second, in addition to using the dichotomized nicotine-
addiction phenotype, we used both the age-adjusted
FTND and the RTQ scores as quantitative measures of
the degree of nicotine dependence. The FTND and the
RTQ are both based on the Fagerstrom Tolerance Ques-
tionnaire (FTQ) (Fagerstrom 1978), and both have im-
proved the internal consistency, the unitary-factor struc-
ture, and the psychometric properties of the FTQ
(Heatherton et al. 1991; Tate and Schmitz 1993). In ad-
dition to covering all six items of the FTND, the RTQ
has included items on inhalation patterns and the pro-
portion of the physical lengths of the cigarettes smoked
(Tate and Schmitz 1993). Thus, RTQ and FTND scores
represent two moderately different perspectives in quan-
tifying the degree of nicotine dependence. The RTQ ap-
pears to be more composite than the FTND, and this may
explain the slight differences we detected by use of these
two closely related continuous phenotypes ( ,rp 0.52
).P ! .0001
The use of the continuously distributed phenotype in
LD analysis has been shown to be a more powerful strat-
egy in detecting genetic susceptibility to complex diseases
than the simple classiﬁcation of individuals into “ad-
dicted” and “nonaddicted” categories (Ebstein et al.
1996; Leckman et al. 2001; Rowe et al. 2001). By treating
nicotine addiction as either a qualitative or a quantitative
phenotype, we found highly consistent results across both
univariate (table 1) and haplotype analyses (tables 2 and
3). In particular, the univariate FBAT found protective
effects of the variant alleles at rs1044396 and rs1044397
against nicotine addiction, whereas the haplotype FBAT
not only corroborated such ﬁndings at the global level
but also revealed that the GCTATA haplotype (bearing
the variant allele at these two loci) had a signiﬁcant pro-
tective effect against nicotine addiction. Unobserved
causal SNPs that are in and surrounding the CHRNA4
gene and are in LD with the observed CHRNA4 markers
may explain the association we found. When we per-
formed direct DNA resequencing for exon 5 ofCHRNA4
in a selected sample, two more synonymous SNPs were
found (indicated as SNP1 and SNP2 in ﬁg. 1), but no
missense or splice-site mutations were detected. A recent
promoter analysis in transgenic mice of the mouse ortho-
logue of the human CHRNA4 gene, chrna4, demon-
strated that the regions either upstream of the transcrip-
tion initiation site or in intron 1 may contain functional
regulatory elements that are important for endogenous
chrna4 gene expression (Watanabe et al. 1998). There-
fore, SNPs located in the 5′ upstream region and in intron
1 of the human CHRNA4 gene may have functional ef-
fects on CHRNA4 gene expression. The SNP rs6090387,
located in the 5′ UTR of CHRNA4, deserves further in-
vestigation.
Third, our study population appeared to be both rel-
atively stable and fairly homogeneous with respect to
lifestyle variables, as well as social and cultural norms
(Niu et al. 2000). Finally, none of the subjects in this
study used nicotine-replacement therapies, such as nic-
otine gums, patches, or nasal sprays, or used tobacco
products other than cigarettes (such as cigars or smoke-
less tobacco); thus, the potential for confounding by
drug interventions or by an unknown cause of infor-
mation bias was at least signiﬁcantly minimized, if not
virtually eliminated.
In conclusion, by use of a family-based design, we
detected signiﬁcant protective effects of variant alleles at
theCHRNA4 SNPs rs1044396 and rs1044397, not only
at the individual SNP level but also at the global hap-
lotype level (GCTATA being the protective haplotype),
against vulnerability to nicotine addiction in men. Thus,
this study provides important new information in the
genetic research on addictive behaviors, pointing out
that theCHRNA4 gene should be more extensively stud-
ied as a critical biological candidate. Since nicotine ad-
diction is a complex trait with signiﬁcant genetic het-
erogeneity, candidate genes other than CHRNA4 and
CHRNB2, such as the genes encoding the D1, D2, and
D4 dopamine receptors and the dopamine transporters
(Bergen and Caporaso 1999), deserve further study. Be-
cause our study was limited to men, further investiga-
tions should also be performed to assess whether these
CHRNA4 and CHRNB2 genes play similarly important
roles in nicotine addiction in women from the same eth-
nic background. Also, our results need to be replicated
in populations of ancestries other than Chinese.
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